According to randomized controlled trials (RCTs), 2BI are non-inferior to first-generation basal insulins (1BI) with regard to the reduction of HbA1c but safer in terms of hypoglycemia and with lower variability [6]. This evidence concerns the gene INS and Hypoglycemia.